UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy

Gil-Nagel, A; Burd, S; Toledo, M; Sander, JW; Lebedeva, A; Patten, A; Laurenza, A; (2017) A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy. Seizure , 54 pp. 61-66. 10.1016/j.seizure.2017.10.015. Green open access

[thumbnail of 1-s2.0-S105913111730688X-main.pdf]
Preview
Text
1-s2.0-S105913111730688X-main.pdf - Published Version

Download (701kB) | Preview

Abstract

PURPOSE: Perampanel is approved for adjunctive treatment of focal seizures, with or without secondarily generalised seizures, and for primary generalised tonic-clonic seizures in people with epilepsy aged ≥12 years. Perampanel was recently approved for monotherapy use for partial seizures in the United States. This study provides insight into the feasibility of perampanel monotherapy in real-world settings. METHODS: This retrospective, non-interventional, multicentre study (NCT02736162) was conducted between January 2013 and March 2016 in specialist epilepsy centres in Europe and Russia. Eligible individuals had a diagnosis of epilepsy and received perampanel primary or secondary monotherapy as routine clinical care. The primary endpoint was proportion of individuals remaining on perampanel monotherapy, after conversion from perampanel adjunctive treatment, at 3, 6, 12, 18 and 24 months (retention rate). RESULTS: Sixty individuals were in the safety set (female, 63%; white, 97%; aged 18 to <65 years, 73%). Most (85%) received secondary monotherapy with perampanel. At study cut-off, 68% of individuals were continuing on perampanel monotherapy (secondary monotherapy: 55%). The median duration of retention was not calculable due to the high number of individuals ongoing on monotherapy. Twelve individuals had treatment-emergent adverse events that started during perampanel monotherapy, the most frequent was dizziness (5%). One serious treatment-emergent adverse event was reported (pneumonia during adjunctive perampanel treatment). CONCLUSIONS: In this small retrospective study of individuals who received perampanel monotherapy, the majority maintained monotherapy. Perampanel monotherapy may be an achievable option in some people with epilepsy.

Type: Article
Title: A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.seizure.2017.10.015
Publisher version: https://doi.org/10.1016/j.seizure.2017.10.015
Language: English
Additional information: This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Antiepileptic drugs, Monotherapy, Perampanel, Real-world setting, Retention rate
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Clinical and Experimental Epilepsy
URI: https://discovery.ucl.ac.uk/id/eprint/10041112
Downloads since deposit
169Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item